Compugen News

Compugen Ltd. announced the discovery and experimental confirmation of a novel combination of four biomarkers for early detection of drug-induced nephrotoxicity.

For additional information, please visit Compugen's corporate Website at http://www.cgen.com and Evogene's corporate Website at http://www.evogene.com . This press release may contain "forward-looking ... via Medical News Today

Feb 19, 2008 - Compugen Ltd. today reported financial results for the fourth quarter and year-end December 31, 2007. via Med Ad News

Compugen Ltd. today announced that the Company plans to host a live conference call and webcast on Tuesday, February 19, 2008 at 10:00 AM EST to review fourth quarter and full year 2007 results. via Business Wire

“We are, of course, very pleased by these successful in-vivo results for CGEN-855A and CGEN-855B which fully support continuing the development of these peptides as anti-inflammatory and cardio-protective drug candidates”

Naomi Rabbie, +972-52-598-9894 Corporate Communications Manager naomir@cgen.com Compugen Ltd. via PR-inside.com

Our Stocks to Watch tomorrow include Universal Detection Technology , Copper King Mining Corporation , Carrington Laboratories, Inc. via M2.com

Electronic Clearing House Being bought by Intuit . Up 110% Oracle Up 7% on strong earnings. via Blogging Stocks

“This agreement is both the first based on our GeneVa platform and also our first collaboration with Roche, one of the world's leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics”

Dec 20, 2007 - Compugen Ltd. announced today that it has signed a collaborative discovery and license agreement with Roche. via Med Ad News

“Our business is growing at a very rapid pace”

Washington Business Journal - by Chris Silva Although the market slowdown has affected the biotech sector as it has other sectors, TherImmune in Gaithersburg has managed to keep its business going at a steady ... via Bizjournals